Keyword Search
Sessions Were Renumbered as of May 19.
Legend:
CC-W = McCormick Place Convention Center, West Building, CC-N = McCormick Place Convention Center, North Building
H = Hilton Chicago, UC= Conference Chicago at University Center
* = applied session ! = JSM meeting theme
|
Keyword Search Criteria: Cancer returned 92 record(s)
|
|
Sunday, 07/31/2016
|
Robust Treatment Comparison Based on Utilities of Semi-Competing Risks in Non-Small-Cell Lung Cancer
Thomas Murray, MD Anderson Cancer Center; Peter F. Thall, MD Anderson Cancer Center; Ying Yuan, MD Anderson Cancer Center; Daniel Gomez, MD Anderson Cancer Center; Sarah McAvoy, MD Anderson Cancer Center
2:05 PM
|
On the Discovery and Use of Disease Risk Factors with Logistic Regression: New Prostate Cancer Risk Factors
David Booth, Kent State University; Venugopal Gopapalakrishna-Remani, The University of Texas at Tyler; Matthew Cooper, Washington University; Fiona Green, University of Manchester; Margaret Rayman, University of Surrey
2:20 PM
|
Two-Stage Design for Phase I/II Cancer Clinical Trials Using Drug Combinations of Cytotoxic Agents
Mourad Tighiouart, Cedars-Sinai Medical Center; Quanlin Li
2:25 PM
|
Network-Based Analysis of Multidimensional Cancer Omics Data
Shuangge Ma, Yale University
2:30 PM
|
Integrative Sparse K-Means for Disease Subtype Discovery
George Tseng, University of Pittsburgh; Zhiguang Huo, University of Pittsburgh
2:30 PM
|
Searching for Gene Sets with Mutually Exclusive Mutations
Paul Ginzberg, Imperial College London; Federico Giorgi, Columbia University; Andrea Califano, Columbia University
2:50 PM
|
New Integrative Paradigms of Personalized Medicine for Cancer
Kim-Anh Do, MD Anderson Cancer Center; Veera Baladandayuthapani, MD Anderson Cancer Center; Francesco Stingo, MD Anderson Cancer Center; Min Jin Ha, MD Anderson Cancer Center; Thierry Chekouo Tekougang, MD Anderson Cancer Center
4:05 PM
|
Combining Safety and Efficacy Data for Assessing Risk Benefit in Cancer Clinical Trials: Some Recent Examples
Thomas Kelleher, Bristol-Myers Squibb
4:05 PM
|
Multiple Imputation Framework to Estimate Causal Effect of Testing on Treatment Decision
Irina Bondarenko, University of Michigan; Yun Li, University of Michigan
4:05 PM
|
Using Meta-Analysis in the Design and Analysis of Early-Phase Cancer Studies
Ashok Panneerselvam, Novartis Oncology; Sofia Paul, Novartis; Suddhasatta Acharyya, Novartis
4:45 PM
|
Shared Frailty in Joint Model of Cancer Incidence, Metastases, and Mortality
Qui Tran, University of Michigan; Kelley M. Kidwell, University of Michigan; Alex Tsodikov, University of Michigan
4:50 PM
|
Regulatory Challenges in Evidence Synthesis in Cancer Clinical Trials
Rajeshwari Sirdhara, FDA
5:05 PM
|
Detecting Association to Precision Networks via Conditional Multi-Type Graphical Models
Yanming Li, University of Michigan; Kevin He, University of Michigan; Jian Kang, University of Michigan; Hyokyoung (Grace) Hong, Michigan State University; Ji Zhu, University of Michigan; Yi Li, University of Michigan
5:20 PM
|
|
Monday, 08/01/2016
|
A Novel Approach to Non-Muscle Invasive Bladder Cancer Trials: Making Lemonade Out of Apples and Oranges
Yuqun Luo, FDA; John Scott, FDA
|
Genome-Wide Transcription Regulation Discovery for Breast Cancer Cell Lines
Zangdong He, Indiana University Fairbanks School of Public Health; Lang Li, Indiana University School of Medicine; Changyu Shen, Indiana University School of Medicine
|
A Bayesian Adaptive Design in Cancer Phase I Trials Using Dose Combinations in the Presence of a Baseline Covariate
Sungjin Kim; Mourad Tighiouart, Cedars-Sinai Medical Center; Marcio Diniz, Cedars-Sinai Medical Center
|
Bayesian Adaptive Designs Using Copula-Type Models in Phase I Cancer Trials Using Drug Combination
Galen Cook-Wiens, Cedars-Sinai Medical Center; Mourad Tighiouart, Cedars-Sinai Medical Center; Marcio Diniz, Cedars-Sinai Medical Center; Andre Rogatko, Cedars-Sinai Medical Center
|
Dose Finding for Drug Combination in Early Cancer Phase I Trials using Conditional Continual Reassessment Method
Quanlin Li; Mourad Tighiouart, Cedars-Sinai Medical Center; Marcio Diniz, Cedars-Sinai Medical Center
|
Estimating Survivor Average Causal Effect of Dynamic Treatment Regimes in Randomized Cancer Clinical Trial: A Simulation Study
Takuya Kawahara, University of Tokyo; Yutaka Matsuyama, University of Tokyo
|
Assessment of Effect Size and Power for Survival Analysis Through a Binary Surrogate Endpoint in Clinical Trials
Judah Abberbock, University of Pittsburgh ; Gong Tang, University of Pittsburgh
|
Using Mixed Model for Repeated Measures to Study the Changes of Physical Function for Breast Cancer Patients with Taxane-Based Chemotherapy
Xueliang Pan; Scott Monfort, The Ohio State University; Ajit Chaudhari, The Ohio State University; Maryam Lustberg, The Ohio State University
|
A New Resampling Method in Linear Regression Model with Application in Cancer Statistics
Huann-Sheng Chen, National Cancer Institute
|
A Bayesian Approach to Evaluating and Prioritizing Pathway Association with Disease
Shu-Ju Lin, National Taiwan University; Chuhsing Kate Hsiao, National Taiwan University
|
Clustering Mutations and Estimating Contamination Rates via Bayesian Nonparametrics
Putu Ayu Sudyanti, Purdue University; Vinayak Rao, Purdue University; Hyonho Chun, Purdue University
|
Assessing Model Fit in Joint Models of Longitudinal and Survival Data with Applications to Cancer Clinical Trials
Joseph G. Ibrahim, The University of North Carolina at Chapel Hill; Ming-Hui Chen, University of Connecticut; Mark Boye, Eli Lilly and Company; Wei Shen, Eli Lilly and Company; Danjie Zhang, Gilead Pharmaceuticals
8:35 AM
|
Integrating Diverse Genomics Data Sets to Improve Precision Medicine in Cancer Treatment
Hongyu Zhao, Yale University
8:35 AM
|
Statistical Issues in Single-Cell Analysis for Cancer Research
Omar De La Cruz Cabrera, Case Western Reserve University
8:55 AM
|
Intratumor Heterogeneity Analysis Using High-Throughput DNA Sequencing Data
Ronglai Shen, Memorial Sloan Kettering Cancer Center; Venkatraman Seshan, Memorial Sloan Kettering Cancer Center
9:15 AM
|
Modeling Micronuclei Count Data Using the Generalized Monotone Incremental Forward Stagewise Method: Application in Women with Breast Cancer
Rebecca Lehman, Virginia Commonwealth University; Colleen Jackson-Cook, Virginia Commonwealth University; Kellie J. Archer, Virginia Commonwealth University
9:20 AM
|
Estimating Tumor Purity/Ploidy and Subclone Structure Using Multiple Types of Omic Data
Chong Jin, The University of North Carolina at Chapel Hill; Wei Sun, Fred Hutchinson Cancer Research Center; Mengjie Chen, The University of North Carolina at Chapel Hill; Danyu Lin, The University of North Carolina at Chapel Hill
9:35 AM
|
Cancer Mortality in USA, 1999--2012: A Review and Inter-State Comparisons
Desale Habtzghi, DePaul University
9:35 AM
|
Effective Experience Analysis of Age-by-Period Data for Japanese Breast Cancer Deaths
Nobutane Hanayama, Shobi University
9:35 AM
|
A Bayesian Approach to Evaluating and Prioritizing Pathway Association with Disease
Shu-Ju Lin, National Taiwan University; Chuhsing Kate Hsiao, National Taiwan University
10:40 AM
|
Profiling Hospitals Based on Degree of Aggressiveness in Treating Patients with Advanced Cancer
Tianyi Cai, Harvard; Sherri Rose, Harvard Medical School; Deborah Schrag, Dana-Farber Cancer Institute; Francesca Dominici, Harvard T.H. Chan School of Public Health
11:35 AM
|
Survival Analysis with Measurement Error in a Cumulative Exposure Variable: Radon Progeny in Relation to Lung Cancer Mortality
Polyna Khudyakov, Harvard T.H. Chan School of Public Health; Jonathan Samet, University of Southern California; Charles Wiggins, University of New Mexico; Xiaomei Liao, Harvard T.H. Chan School of Public Health; Angela Meisner, New Mexico Tumor Registry; Donna Spiegelman, Harvard T.H. Chan School of Public Health
11:35 AM
|
Clustering Mutations and Estimating Contamination Rates via Bayesian Nonparametrics
Putu Ayu Sudyanti, Purdue University; Vinayak Rao, Purdue University; Hyonho Chun, Purdue University
11:55 AM
|
Case-Oriented Pathways Analysis in Pancreatic Adenocarcinoma
Yen-Yi Ho, University of Minnesota; Timothy K. Starr, University of Minnesota; Rebecca S. LaRue, Minnesota Super Computing Institute; David A. Largaespada, University of Minnesota
2:05 PM
|
Modeling Multiple Primary Cancers Over Time Using a Novel Familywise Likelihood Under the Nonhomogeneous Poisson Process
Jialu Li, MD Anderson Cancer Center; Seung Jun Shin, Korea University; Wenyi Wang, MD Anderson Cancer Center
2:05 PM
|
Analysis of High-Throughput Drug Screening Data of Cancer Cell Lines
Hongmei Liu; J. Sunil Rao, University of Miami
2:50 PM
|
Assessing Intra-Tumor Heterogeneity and Tracking Longitudinal and Spatial Clonal Evolution by Next-Generation Sequencing
Yuchao Jiang, University of Pennsylvania; Yu Qiu, University of Pennsylvania; Andy J. Minn, University of Pennsylvania; Nancy Zhang, University of Pennsylvania
3:05 PM
|
A Beta-Binomial Model to Compare Somatic Mutation Rates Between Groups of Cancer Patients
Hong Wang, University of Kentucky; Yong Chen, University of Pennsylvania Perelman School of Medicine; Jinze Liu, University of Kentucky; Heidi Weiss, University of Kentucky ; Susanne M. Arnold, University of Kentucky; Aronld Stromberg, University of Kentucky; Chi Wang, University of Kentucky
3:20 PM
|
Adaptively Choosing Hyperparameters for Non-Local Priors in High Dimensional Bayesian Variable Selection
Amir Nikooienejad, Texas A&M University; Valen E. Johnson, Texas A&M University
3:35 PM
|
|
Tuesday, 08/02/2016
|
High-Dimensional Cox Regression for Genome-Wide Assessment of the Prognostic Benefit of Somatic Mutations in Ovarian Cancer
Brandon Butcher, University of Iowa; Patrick Breheny, University of Iowa; Donghai Dai, University of Iowa
|
Topological Tools for the Classification of Breast Cancer from Histology Images
Patrick Medina, Purdue University; Rebecca W. Doerge, Purdue University
|
Prediction of Lung Cancer Risk in the CT Arm of the National Lung Screening Trial
Menghan Hu, Brown University; Fenghai Duan, Brown University
|
Use of the Treatment-Free Interval in Driving Decision Making in Cancer Care: A Late-Phase Example
Suddhasatta Acharyya, Novartis; Ashok Panneerselvam, Novartis Oncology; Sofia Paul, Novartis
|
Impact of Mis-Specified Prior on the Bayesian Dose-Finding Method in Phase I Cancer Trials
Lixia Pei, Janssen R&D; Kevin Liu, Janssen R&D; Hong Tian, Janssen R&D
|
Tumor Response in Patients Receiving No Anti-Cancer Therapy: A Meta-Analysis with Incomplete Multinomial Regression
Charity Morgan, University of Alabama at Birmingham; Pooja Ghatalia, University of Alabama at Birmingham; Guru Sonpavde, University of Alabama at Birmingham
|
Prediction of Lung Cancer Risk in the CT Arm of the National Lung Screening Trial
Menghan Hu, Brown University; Fenghai Duan, Brown University
8:40 AM
|
Discriminating Among Correlated Aspects of Exposure
Robert Hirsch, Stat-Aid Consulting
9:05 AM
|
Impact of Mis-Specified Prior on the Bayesian Dose-Finding Method in Phase I Cancer Trials
Lixia Pei, Janssen R&D; Kevin Liu, Janssen R&D; Hong Tian, Janssen R&D
9:05 AM
|
Tumor Response in Patients Receiving No Anti-Cancer Therapy: A Meta-Analysis with Incomplete Multinomial Regression
Charity Morgan, University of Alabama at Birmingham; Pooja Ghatalia, University of Alabama at Birmingham; Guru Sonpavde, University of Alabama at Birmingham
9:05 AM
|
Use of the Treatment-Free Interval in Driving Decision Making in Cancer Care: A Late-Phase Example
Suddhasatta Acharyya, Novartis; Ashok Panneerselvam, Novartis Oncology; Sofia Paul, Novartis
10:10 AM
|
Generalized Fiducial Inference for Massive Heterogeneous Data
Jan Hannig, The University of North Carolina at Chapel Hill
11:25 AM
|
Integrated DNA Mutation, Copy Number, and Gene Expression Analysis Reveals a Highly Reproducible Prognostics Marker in Lung Adenocarcinomas
Hao Ho, University of California at Los Angeles
11:35 AM
|
Adapting Heterogeneous Tissue Expression Analysis Method to RNA-Seq Data
Megan Stefanski, University of Missouri - Kansas City; David Spade, University of Missouri - Kansas City
11:35 AM
|
Robust Approaches for the Analysis of High-Throughput Proteomic Data
Naim Rashid
11:50 AM
|
Spatial Prediction of Naturally Occurring Indoor Gamma Radiation Dose Rates in Great Britain
Mark Peter Little, National Cancer Institute; Pavel Chernyavskiy, National Cancer Institute; Gerald M. Kendall, University of Oxford; Philip S. Rosenberg, National Cancer Institute; Richard Wakeford, University of Manchester
2:05 PM
|
Using IMRE and Dual KS to Select MicroRNAs for Predicting Prostate Cancer
Yarong Yang, North Dakota State University
2:20 PM
|
Competing Risks Model of Cancer Screening and Symptomatic Diagnosis
Sheng Qiu; Alex Tsodikov, University of Michigan
2:20 PM
|
Statistical Applications for Ethnic Disparities in Breast Cancer Survival Data
Hafiz Khan, Texas Tech University Health Sciences Center El Paso; Rachel N. Smith, Texas Tech University Health Sciences Center El Paso
3:35 PM
|
|
Wednesday, 08/03/2016
|
Ten Essential Elements for Developing or Reforming a Biostatistics Core for a Cancer Center with (or Aspiring for) NCI Designation
Erin Moshier, Icahn School of Medicine at Mount Sinai; Umut Ozbek, Icahn School of Medicine at Mount Sinai; Madhu Mazumdar, Icahn School of Medicine at Mount Sinai
|
Finding Optimal Combination in Cancer Drug Development: An Evidence Synthesis Approach
Sofia Paul, Novartis; Fei Ma, Novartis; Satrajit Roychoudhury, Novartis
|
Pathway-Structured Predictive Model for Cancer Survival Prediction
Xinyan Zhang, University of Alabama at Birmingham; Yan Li, University of Alabama at Birmingham; Omotomilayo F. Akinyemiju, University of Alabama at Birmingham; Akinyemi I. Ojesina, University of Alabama at Birmingham; Phillip Buckhaults, University of South Carolina; Bo Xu, Southern Research Institute; Nengjun Yi, University of Alabama at Birmingham
|
Adaptive Estimation of Personalized Maximum Tolerated Doses in Cancer Phase I Clinical Trials According to All Toxicities and Individual Characteristics
Zhengjia Chen, Emory University; Zheng Li, Penn State University; Ying Yuan, MD Anderson Cancer Center; Michael Kutner, Emory University; Taofeek Owonikoko, Emory University; Walter J. Curran, Emory University; Jeanne Kowalski, Emory University
|
Statistical Methods for Genomic Data Integration
Veera Baladandayuthapani, MD Anderson Cancer Center
8:35 AM
|
Using Propensity Scores to Infer Causal Effects on Heart Health from Chemotherapy Treatment of Breast Cancer Patients
John Craycroft, University of Louisville; Maiying Kong, University of Louisville; Carrie Lenneman, University of Louisville
8:35 AM
|
Adaptive Estimation of Personalized Maximum Tolerated Doses in Cancer Phase I Clinical Trials According to All Toxicities and Individual Characteristics
Zhengjia Chen, Emory University; Zheng Li, Penn State University; Ying Yuan, MD Anderson Cancer Center; Michael Kutner, Emory University; Taofeek Owonikoko, Emory University; Walter J. Curran, Emory University; Jeanne Kowalski, Emory University
8:45 AM
|
Adaptive Models for Profiling Tumor Evolution and Drug Response in Cancer Cell Subpopulations
Evan Johnson, Boston University
8:50 AM
|
Pathway-Structured Predictive Model for Cancer Survival Prediction
Xinyan Zhang, University of Alabama at Birmingham; Yan Li, University of Alabama at Birmingham; Omotomilayo F. Akinyemiju, University of Alabama at Birmingham; Akinyemi I. Ojesina, University of Alabama at Birmingham; Phillip Buckhaults, University of South Carolina; Bo Xu, Southern Research Institute; Nengjun Yi, University of Alabama at Birmingham
8:55 AM
|
A Gaussian-Probit Model for Bayesian Network with Mixed Variables
Qingyang Zhang, University of Arkansas; Ji-Ping Wang, Northwestern University
9:35 AM
|
Dynamic Scheduling of the Next Exam in Cancer Screening
Dongfeng Wu, University of Louisville
10:35 AM
|
A Bayesian Approach to Smoothed Lexis Diagram with Applications to Breast Cancer
I-Shou Chang, National Health Research Institutes
10:35 AM
|
A Permanental Approach in Predicting the Relapse Risk of Breast Cancer
Haipeng Liu, University of Illinois at Chicago; Jie Yang, University of Illinois at Chicago
10:50 AM
|
Comparisons of Statistical Methods for Determining Gene Expression Signatures to Predict Prostate Cancer Response
Dirk Moore, Rutgers School of Public Health; Qian Dong, Celgene
11:05 AM
|
Propensity Score Approach for Multiple Treatment Options and Its Application in Cancer Outcome Research
Yuan Liu; Jeanne Kowalski, Emory University; Theresa Wicklin Gillespie, Emory University
11:20 AM
|
Integrated Kernel Learning for Genomic Data Mining and Prediction
Xuefeng Wang, SUNY Stony Brook; Zhenyu Zhang, SUNY Stony Brook; Minqin Chen, SUNY Stony Brook
11:25 AM
|
Predicting Pathologic Complete Response Using Clinical and Microarray Data in the Presence of a Dominating Class
Jonathon Abernethy, University of Illinois at Chicago; Jie Yang, University of Illinois at Chicago
11:35 AM
|
Spatial-Nonspatial Multidimensional Adaptive Radiotherapy Treatment
David Vock, University of Minnesota School of Public Health; Guadalupe M. Canahuate, University of Iowa; G.Elisabeta Marai, University of Illinois at Chicago; C. David Fuller, MD Anderson Cancer Center
11:55 AM
|
Collection of Adverse Events Data for the Supplemental Indications in Cancer Clinical Trials: Is It Needed?
Sirisha Mushti, FDA; Huanyu Chen, FDA; Yun Wang, FDA; Rajeshwari Sridhara, FDA
12:05 PM
|
Functional Variations of Cancer Mortality Rates
Keshav Pokhrel, University of Michigan
3:05 PM
|
Improved Designs and Analyses of Safety and Efficacy in Immuno-Oncology
Bo Huang, Pfizer; Margarida Geraldes, Pfizer
3:25 PM
|
Estimating and Accounting for Tumor Purity in Methylation Microarray Analysis
Hao Wu, Emory University
3:25 PM
|
|
Thursday, 08/04/2016
|
Combining Information from Two Data Sources with Misreporting and Incompleteness to Assess Hospice-Use Among Cancer Patients: A Multiple Imputation Approach
Yulei He, CDC; Mary-Beth Landrum, Harvard Medical School; Alan M. Zaslavsky, Harvard Medical School
8:35 AM
|
Integrative Subtype Analysis of Ovarian Cancer Using Non-Negative Matrix Factorization
Prabhakar Chalise, University of Kansas Medical Center; Ellen L. Goode, Mayo Clinic; Brooke L. Fridley, University of Kansas Medical Center
8:35 AM
|
Multivariate Latent Structure in Bayesian Spatio-Temporal Health Models
Andrew B. Lawson, Medical University of South Carolina
9:25 AM
|
Estimating the Optimal Regime to Prolong Survival in Treatment of Prostate Cancer Recurrence Using Flexible Weighting Models
Jincheng Shen, Harvard T.H. Chan School of Public Health; Lu Wang, University of Michigan; Jeremy M. G. Taylor, University of Michigan
9:25 AM
|
Design Immunotherapy Trials with Delayed Treatment Effect
Zhenzhen Xu, FDA; Boguang Zhen, FDA; Yongseok Park, University of Pittsburgh; BIN ZHU, National Cancer Institute
10:35 AM
|
Bayesian Mixture Response Analysis for Pre-Clinical in Vivo Anti-Cancer Drug Efficacy Investigations
David Gold, Bristol-Myers Squibb; Ningning Chen, Apple
10:50 AM
|
Better Use of Family History Data to Predict Breast Cancer Risk
Shanshan Zhao, National Institute of Environmental Health Sciences; Clare Weinberg, National Institute of Environmental Health Sciences; Yue Jiang, The University of North Carolina at Chapel Hill
10:50 AM
|
Sample Size Methods for Validating Treatment Selection Cancer Biomarkers from Right-Censored Survival Data
Kevin Dobbin, University of Georgia; Lisa M. McShane, National Cancer Institute
11:05 AM
|
Alcohol Consumption, BMI, and Colorectal Cancer
Negasi Beyene, CDC/NCHS
12:05 PM
|
|
|
